GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Tenet Healthcare Corp (NYSE:THC) » Definitions » 10-Year RORE %

Tenet Healthcare (Tenet Healthcare) 10-Year RORE % : 54.47% (As of Dec. 2023)


View and export this data going back to 1976. Start your Free Trial

What is Tenet Healthcare 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Tenet Healthcare's 10-Year RORE % for the quarter that ended in Dec. 2023 was 54.47%.

The industry rank for Tenet Healthcare's 10-Year RORE % or its related term are showing as below:

THC's 10-Year RORE % is ranked better than
90.56% of 286 companies
in the Healthcare Providers & Services industry
Industry Median: 7.095 vs THC: 54.47

Tenet Healthcare 10-Year RORE % Historical Data

The historical data trend for Tenet Healthcare's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenet Healthcare 10-Year RORE % Chart

Tenet Healthcare Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 377.04 -45.87 850.00 153.82 54.47

Tenet Healthcare Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 153.82 83.64 72.46 65.68 54.47

Competitive Comparison of Tenet Healthcare's 10-Year RORE %

For the Medical Care Facilities subindustry, Tenet Healthcare's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenet Healthcare's 10-Year RORE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Tenet Healthcare's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Tenet Healthcare's 10-Year RORE % falls into.



Tenet Healthcare 10-Year RORE % Calculation

Tenet Healthcare's 10-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( 5.71-0.1 )/( 10.3-0 )
=5.61/10.3
=54.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 10-year before.


Tenet Healthcare  (NYSE:THC) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Tenet Healthcare 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Tenet Healthcare's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenet Healthcare (Tenet Healthcare) Business Description

Traded in Other Exchanges
Address
14201 Dallas Parkway, Dallas, TX, USA, 75254
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 60 as of June 2023) and over 550 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
Executives
Richard W Fisher director
Roy Blunt director 2702 LOVE FIELD DRIVE, HDQ 4GC, DALLAS TX 75235
Paola M Arbour officer: EVP, Chief Information Officer 14201 DALLAS PARKWAY, DALLAS TX 75254
Stephen H Rusckowski director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Thomas W Arnst officer: EVP, Chief Admin. Officer & GC 14201 DALLAS PARKWAY, DALLAS TX 75254
Tammy Romo director C/O SOUTHWEST AIRINES CO., 2702 LOVE FIELD DR., DALLAS TX 75235
Daniel J Cancelmi officer: Principal Accounting Officer 13737 NOEL ROAD, SUITE 100, DALLAS TX 75240
J Robert Kerrey director NEW SCHOOL UNIVERSITY, 66 W. 12TH STREET, NEW YORK NY 10036
Richard J Mark director 1901 CHOUTEAU AVENUE MC-1310, ST. LOUIS MO 63103
Ronald A Rittenmeyer director 5400 LEGACY DRIVE, PLANO TX 75024
Lisa Y Foo officer: EVP, Commercial Ops 14201 DALLAS PARKWAY, DALLAS TX 75254
Audrey T. Andrews officer: SVP and General Counsel 1445 ROSS AVENUE, SUITE 1400, DALLAS TX 75202
Meghan Fitzgerald director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Howard Hacker officer: EVP, Chief Compliance Officer 14201 DALLAS PARKWAY, DALLAS TX 75254
Marie Quintana officer: EVP, Marketing/Communications 14201 DALLAS PARKWAY, DALLAS TX 75254